Vedanta Biosciences, Inc.

This early-stage study tested whether adding a new investigational therapy called VE800—a preparation of specific bacteria—could improve the effectiveness of an existing immunotherapy drug (nivolumab) in patients with advanced or metastatic cancers. The trial enrolled 56 patients…